These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 26724400)
1. Use of computer simulations to test the concept of dose forgiveness in the era of extended-release (XR) drugs. Pellock JM; Brittain ST Epilepsy Behav; 2016 Feb; 55():21-3. PubMed ID: 26724400 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Brittain ST; Wheless JW Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125 [TBL] [Abstract][Full Text] [Related]
3. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation. Chen C; Wright J; Gidal B; Messenheimer J Ther Drug Monit; 2013 Apr; 35(2):188-93. PubMed ID: 23503444 [TBL] [Abstract][Full Text] [Related]
4. Extended-release formulations for the treatment of epilepsy. Bialer M CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575 [TBL] [Abstract][Full Text] [Related]
5. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Gidal BE; Clark AM; Anders B; Gilliam F Epilepsy Res; 2017 Jan; 129():26-32. PubMed ID: 27883934 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Gordi T; Hou E; Kasichayanula S; Berner B Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937 [TBL] [Abstract][Full Text] [Related]
7. Conversion from immediate-release to extended-release lamotrigine improves seizure control. Ramey P; Osborn M; Abou-Khalil B Epilepsy Res; 2014 Nov; 108(9):1637-41. PubMed ID: 25205163 [TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077 [TBL] [Abstract][Full Text] [Related]
9. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects. Anderson GD; Saneto RP CNS Drugs; 2015 Aug; 29(8):669-81. PubMed ID: 26369919 [TBL] [Abstract][Full Text] [Related]
10. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions. Conner TM; Reed RC; Zhang T Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of extended-release topiramate in patients with epilepsy: A two-year retention study. Lee H; Kim DW J Clin Pharm Ther; 2021 Oct; 46(5):1412-1417. PubMed ID: 34146432 [TBL] [Abstract][Full Text] [Related]
19. What do the suffixes--XR, ER, Chrono, Chronosphere--really mean as it pertains to modified-release antiepileptic drugs? Reed RC; Meinhold J; Dutta S; Liu W; Qiu Y J Clin Pharm Ther; 2010 Aug; 35(4):373-83. PubMed ID: 20831540 [TBL] [Abstract][Full Text] [Related]
20. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Riesenberg RA; Baldytcheva I; Datto C Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]